These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 37020035)
1. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035 [TBL] [Abstract][Full Text] [Related]
2. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552 [TBL] [Abstract][Full Text] [Related]
3. Anti-tumor efficacy of a potent and selective non-covalent KRAS Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931 [TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487 [TBL] [Abstract][Full Text] [Related]
5. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318 [TBL] [Abstract][Full Text] [Related]
6. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer. Ye H; Liu Y; Wu K; Luo H; Cui L Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218 [TBL] [Abstract][Full Text] [Related]
7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137 [TBL] [Abstract][Full Text] [Related]
8. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279 [TBL] [Abstract][Full Text] [Related]
9. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296 [TBL] [Abstract][Full Text] [Related]
10. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239 [TBL] [Abstract][Full Text] [Related]
11. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111 [TBL] [Abstract][Full Text] [Related]
12. Inhibition mechanism of MRTX1133 on KRAS Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761 [TBL] [Abstract][Full Text] [Related]
19. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. Kim S; Kim N; Kang K; Kim W; Won J; Cho J Cells; 2019 Aug; 8(8):. PubMed ID: 31409052 [TBL] [Abstract][Full Text] [Related]
20. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]